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ABSTRACT
BACKGROUND: Recurrence of medulloblastoma appears after 30% to 40% of the surgeries. Different
from primary medulloblastoma, in which five-year survival rate is 50%, the survival time of relapses
much shorter and only 20% of the patients manage to survive a year. There is a logical need for addi-
tional methods of treatment of recurrent medulloblastomas. The aim of the study is to determine the
effects of intracavitary and long-term subcutaneous application of Sandostatin (octreotide) on the recur-
rent medulloblastomas. 
METHODS: Fourteen children aged 4 to 9 years, in which, despite of craniospinal irradiation and
chemotherapy came to a recurrence of medulloblastoma during the first 6 months after the surgery,
were treated subcutaneously with Sandostatin (octreotide) in a longer period of time. Cerebellar medul-
loblastomas with a diameter bigger than 20 mm and spinal over 10 mm were removed operatively and
octreotide with Beriplast was applied intracavitary.
RESULTS: Magnetic resonance of cranioaxis shows that the application of octreotide has caused the
disappearance of spinal drop metastases in all 7 patients and the cerebellar metastases smaller than 5
mm in all 4 patients. Subcutaneous application of octreotide combined with intracavitary expresses an
antitumoral effect in 2/3 of the relapses. The application of octreotide results with a transformation of
Chang￿s stage M0 into M1 in 71.43% of the patients.
CONCLUSION: In the case of in loco or metastatic recurrence of medulloblastomas, intracavitarily and
subcutaneously applied octreotide results with a regression of the tumor in a 3 year time within 2/3 of
the treated patients.
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INTRODUCTION 
M
edulloblastoma is the most frequent embryonic tumor of the central nervous system
(CNS), which appears before the 10th year of life in 75% of the cases, and twice more
often in boys (1). Recurrence of medulloblastoma appears in 30%-40% of the operated
patients, most frequently on the position of the previous surgery. A medulloblastoma can
reach the spinal cord or other parts of the CNS by the dissemination of the cerebrospinal
liquid, while the disseminations out of CNS are very rare. Medical response to a recurrence
is a new surgery and an aggressive irradiation and cytostatic therapy on the complete cran-
ioaxis. Certain number of children does not manage to stand the complete therapy, and
those who do stand it, have severe problems, especially in neurocognitive functions, con-
centration, and intelligence (2-5). Different from primary medulloblastoma, in which five-
year survival rate is 50%, the survival time of recurrence is much shorter, and only 20% of
the patients manage to survive a year. There is a logical need for additional methods of
treatment of recurrent medulloblastomas.  Certain peptidomemethichs such as  synthetic
somatostatin (octreotide) can reduce the level of intracellular cAMP for more than 70% by
direct activation of specific receptors on the tumor cells. They can also increase the activ-
ity of potassium (K) pump through triggering hyperpolarization of the cell membrane, dis-
abling the potassium to enter the cytosol, what blocks numerous enzymatic systems and
lead the cell into apoptosis (6). Adding the already known indirect antitumor mechanism of
octreotide based on the suppression of neovascularisation and lower secreting of growth
factors (growth factor, secretin, gastrin...) which are used by the tumor for its growth, ini-
tiates the idea of testing octreotide in the therapy of incompletely resected medulloblas-
tomas or their metastases.
The aim of the study was to determine the effects of intracavitary and long-term subcuta-
neous application of Sandostatin on medulloblastoma recurrences and metastases, from
the aspect of influence on tumor growth or involution. The task was also to evident eventu-
al difference in effects, depending on the method of octreotide application.
PATIENTS AND METHODS
The study observes 14 patients (9 boys and 5 girls), aged 4 to 9 years (average 6), who
developed a recurrence of medulloblastoma during the first 6 months after a surgery of a
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CNS. According to the SIOP criteria, all of the patients belonged to the group of high-risk
medulloblastomas, and after the primary surgery had a full BCNU protocol and irradiation of
cranioaxis of 35Gy. Recurrences of the fossa posterior with a diameter bigger than 20 mm
and spinal medulloblastomas with a diameter bigger than 10 mm were operatively removed
and at the same time, octreotide mixed with Beriplast (1:2) was applied. The total volume
of the depot medicament was determined according to the following original formula: 
V(ml)= 0.4185   x     a x b x c / a + b + c 
where a, b, and c are the preoperative measures of each tumor in the 3 planes seen in  a
post contrast computer tomography (CT) scan or magnetic resonance (MR). The surgeries
of recurrences were conducted only in prone position, in order to minimalize the risk of
descendent tumor dissemination by the cerebrospinal fluid (CSF).
Starting from the postoperative day one, patients received a subcutaneous application of
Sandostatin in separate doses of 200 micrograms, 3 times a day, during the following 3
weeks. From the 2nd month on, every 15th day they received 30 mg of Sandostatin LAR -
into the inguinal region.
Metastases smaller than 5 mm and drop metastases were treated only by subcutaneous
application of octreotide. Oncological treatment was not repeated because of the short inter-
val since its end. The following up term lasted 2-4 (average 3) years. The effects of the ther-
apy were monitored by:
1) MR or CT (complete effect (CE)= removal of the tumor, partial effect (PE)=reduction of
tumor￿s volume for more than 25%, stabilization effect (SE)= reduction of growth of
tumor￿s volume for less than 25% and no effect (NE)= growth of tumor￿s volume for more
than 25% or emerging of new metastases). During the first year since the evidencing of
recurrence, a control MR of cranioaxis was done every 3 months and later every six
months. During the third year of the monitoring of the patients with an isolated recurrence
of cerebellar medulloblastoma, one control was done with a contrast CT of brain.
2) Analysis of cerebrospinal fluid on the presence of the tumor cells on the surgery day and
once in 3 months by lumbar puncture in the first year since the beginning of the therapy by
octreotide, and later once in 6 months (M0 - without tumor cells, M1 - with tumor cells).
RESULTS
Chang￿s ￿M stage￿ has shown in 14 recurrences of medulloblastoma: M4 in 7 (50%), M3
in 4 (28.60%) and M2 in 3 (21.40%) patients (Table 1). Out of 8 patients with cerebellar
medulloblastoma recurrences, isolated existence of recurrence on the place of previous
medulloblastoma was recorded in only one patient. The existence of cerebellar medul-
loblastoma recurrence in the remaining 7 patients was followed by additional localizations
of medulloblastoma. Out of 14 patients with medulloblastoma recurrence, spinal drop
metastases were recorded in 8 patients and spinal metastases bigger than 5 mm in cervi-
cal or thoracic region were found in 6 patients. Medulloblastoma metastases of fossa cranii
posterior (FCP) were recorded in 4 patients, in 2 of which, they were the only signs of the
recurrence. One patient had a relapse in the position which was previously operated, an
intramedullar metastasis in the cervical (C4-C7) and thoracolumbar region (Th3-4) region,
and numerous drop metastases inside of the thoracolumbar region of the spinal cord at the
same time.
The application of octreotide resulted with a total disappearance of spinal drop metastases
in all 7 patients after six months (Table 1, Figure 1). Drop metastases and metastases with
a diameter †5 mm in FCP completely involuted in all 4 patients (Figure 2, p<0.001). Spinal
metastases bigger than 5 mm did not give any significant therapy response to the long-term
subcutaneous application of octreotide, except of the cases of microsurgical removal of
medulloblastoma recurrence and intracavitary application of octreotide (Table 1, Figure 3).
Intracavitary application of octreotide resulted in 2/3 of the patients with a microsurgical
resection of the cerebellar recurrence of the medulloblastoma - an absolute disappearance
of tumors on the control scan, which were made in the 6th and the following months, while
the remaining 1/3 expressed of partial reduction of the size or its stabilization (Table 1,
Figure 4). Long-term subcutaneous application of octreotide without the intracavitary appli-
cation of the same medicament did not prevent the progression of cerebellar rest-recur-
rence.
During the analysis of CSF in purpose of Chang￿s M staging, a transformation of M1 into
M0 in the 6th month was recorded, and showed a trend of persistence in 10 (71.43%) of
14 patients, and the same transformation was totally missing in all patients with a recur-
rence or a metastasis larger than 5 mm, unless they were treated by intracavitary applica-
tion of Beriplast and octreotide (Table 1, p<0.001).
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Figure 1. MR of thoracolumbar spine in a patient with medulloblastoma drop metastases:
A) Numerous drop metastases in the spinal cord;   B) Absence of visible drop metastases
6 months after a six-month octreotide therapy
Table 1. Effects of the treatment of recurrent medulloblastomas with intracavitary and sub-
cutaneous application of octreotideDuring a 3-year monitoring period there was only one death, and it was recorded in the 27th
month since the recurrence was evidenced, in a nine-year old boy with a cerebellar recur-
rence and a thoracic metastasis larger than 5 mm, which did not fulfill the conditions for
intracavitary application of octreotide.
Intracavitary application of octreotide in one patient was followed by signs of local obstruc-
tion of the circulation of cerebrospinal fluid, for that reason a ventriculoperitoneal shunt was
installed. No local intolerant reactions or significant gastrointestinal problems were record-
ed during the subcutaneous application of octreotide.
DISCUSSION
It is an up-to-date doctrine to treat recurrent medulloblastomas with an aggressive onco-
logical therapy. High-dose chemotherapy with the accompanied autologous transplantation
of stem cells offers encouraging results in the treatment of recurrent medulloblastomas
(7,8).   
Intraoperative application of MR can contribute to a more complete resection of the tumor.
Unfortunately, a medulloblastoma often approaches the bottom of the fourth  ventricle and
a part of brain stem. The border between the medulloblastoma and the neighboring tissues
is an additional risk for the recurrence of the tumor and its dissemination. Therefore, find-
ing of new therapy possibilities  which do not have significant side effects is very important
in prolonging of the period before the recurrence.
A characteristic of medulloblastoma cells is high presence of somatostatin receptors type
2 (SSR2). Through their activation, the level of cell ATP, synthesis of nucleic acids and
complete metabolic activity of  the cell are reduced, and the final outcome of those process-
es is the apoptosis of the tumor cell (9). 
The disappearance of spinal drop and cerebellar metastases smaller then 5 mm fully suits
the described antitumor effect of octreotide (a synthetic analog of somatostatin). The com-
bined application of octreotide with long-term subcutaneous application and intracavitary
depot application accomplishes a powerful apoptotic effect on the cells of the medul-
loblastoma, even in the cerebrospinal fluid. A scarce vascularization of medulloblastoma in
comparison with malignant gliomas reduces the level of its penetration in deeper parts of
the tumor. Therefore the medulloblastomas with a diameter bigger than 5 mm do not give
an adequate therapy response to the subcutaneous application of depot octreotide.
Intracavitary application of fibrin glue Beriplast with successive degradation does not only
enable a several week local presence of octreotide, but also reduces the dissemination of
the cells of the medulloblastoma into the cerebrospinal fluid by the adhesive mechanism.
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Figure 2. MR of brain in a patient with a cerebellar medulloblastoma recurrence WHO gr. IV
and medulloblastoma metastases in the brain stem: A) Before the surgery, a big cerebel-
lar medulloblastoma with a necrotic zone (thick arrow) and two smaller metastases (nar-
row arrows) are visible.   B) Three months after removing the recurrence and an intracav-
itary application of octreotide, the mass of the medulloblastoma in the tumor cavity (thick
arrow) is smaller, there is one metastasis less in the brain stem, and another one is
reduced.   C) 6 months after the surgery and the octreotide treatment, there are no remain-
ing of medulloblastoma.   D) 2 years after the surgery and the octreotide treatment, there
are still no signs of relapse
Figure 3. MR of the cranioaxis 16 months after the cerebellar medulloblastoma surgery,
and 6 moths after a cervical metastasis surgery:   A) cervical recurrence over 5 mm (thick
arrow) and a satellite drop metastasis (narrow arrow) before intracavitary application of
octreotide;   B) 3 months since the beginning of the octreotide treatment, there is no longer
a cervical drop metastasis, and the cervical recurrence is smaller;  C) 6 months since the
beginning of the octreotide application the cervical recurrence has totally involuted
Figure 4. Cerebellar medulloblastoma before and after the relapse: A) CT of brain  in a four-
year old-boy with a primary medulloblastoma WHO grade IV;   B) MR of brain 3 months
after a primary medulloblastoma surgery (the arrow marks the signs of an initial recur-
rence);   C) MR of brain 6 months after a primary cerebellar medulloblastoma surgery  (the
recurrence has the size of the primary tumor);   D) CT of brain 2 years after the medul-
loblastoma recurrence surgery an intracavitary and subcutaneous application of octreotide
(there are still no signs of a new relapse)Prone position during the surgery, combined with intracavitary application of depot
octreotide, can significantly prevent emerging of spinal metastases.
The absence of complications in prolonged subcutaneous application of octreotide with an
evident positive effect in suppression of recurrent medulloblastomas is the best recom-
mendation for its implementation.
CONCLUSION
Prolonged subcutaneous application of octreotide results with a disappearance of all small-
er metastases of medulloblastomas. Subcutaneous application of octreotide in the therapy
for medulloblastoma recurrences or metastases bigger than 5 mm causes no significant
antitumor effects. Intracavitary application of depot octreotide is an appropriate way of long-
term increasing penetration of octreotide into deeper parts of medulloblastoma rests and
increases octreotide￿s antitumor effect. Medulloblastoma recurrences and metastases with
a diameter bigger than 5 mm, apart from prolonged subcutaneous application of octreotide
demand a surgical resection of recurrence and an intracavitary application of depot
octreotide. The size of the sample of this study is limited by medulloblastoma￿s small par-
ticipation in the number of all CNS tumors, as well as by the small number of primary ver-
ified metastases. The initial results in the prolonged intracavitary application combined with
intracavitary application show that octreotide could be a useful adding to the existing surgi-
cal and oncological therapy of highly malignant medulloblastomas and their metastases.
Further studies involving a bigger number of medulloblastomas in which the results of
octreotide application could be correlated with the density of somatostatin-specific recep-
tors, especially SSR type 2, could in a more exact way approve or deny the antitumor effect
of octreotide notified in this study.
Octreotide is recommended as a powerful additional therapy, together with surgical, irradi-
ation and high-dose chemotherapy, at the moment of  the diagnosis of a primary high-risk
medulloblastoma, and especially in case of its recurrence or a metastasis.
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